CLEVELAND, Ohio — A genomic test used to assess prostate cancer risk may also help doctors determine which patients are ...
Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. "Our ...
The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...
A LASSO-based risk score built from oxidative stress-related genes predicts biochemical recurrence in prostate cancer, with ...
Please provide your email address to receive an email when new articles are posted on . Use of a precision navigator led to significant increase in genomic profiling among men with prostate cancer.
Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysisSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. ( ...
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit ...
A BMC Cancer abstract reports that public-dataset modeling identified a four-gene prognostic model for prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results